David sent a message to Mark Bertolini – Chairman and Chief Executive Officer of Aetna – Email Address that said:
I have been denied coverage by your company for an allograft replacement operation to correct an osteochondral defect in my left talus. The denial is based on the supposition that this is an "experiemental" procedure despite providing the examiner with articles published in peer reviewed journals demonstrating the superiority of the procedure to the established ankle fusion option.
